Volume 14, Issue 8, Pages (December 2011)

Slides:

Advertisements

Similar presentations

Consolidated Health Economic Evaluation Reporting Standards (CHEERS)— Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication.

Advertisements

A Meta-Analysis of Osteoporotic Fracture Risk with Medication Nonadherence Susan Ross, MD, FRCPC, Ebony Samuels, PhD, Kerry Gairy, MSc, Sheikh Iqbal, MD,

Program-Specific Cost-Effectiveness Analysis: Breast Cancer Screening Policies for a Safety-Net Program Joy Melnikow, MD, MPH, Daniel J. Tancredi, PhD,

Cost-Effectiveness of Incobotulinumtoxin-A with Flexible Treatment Intervals Compared to Onabotulinumtoxin-A in the Management of Blepharospasm and Cervical.

Cost-Effectiveness of Sensor-Augmented Pump Therapy in Adults with Type 1 Diabetes in the United States Shital Kamble, PhD, Kevin A. Schulman, MD, Shelby.

Cost-Effectiveness of Partially Hydrolyzed Whey Protein Formula in the Primary Prevention of Atopic Dermatitis in At-Risk Urban Filipino Infants Abhijeet.

Bendamustine Versus Chlorambucil for the First-Line Treatment of Chronic Lymphocytic Leukemia in England and Wales: A Cost-Utility Analysis Beth Woods,

Volume 14, Issue 8, Pages (December 2011)

Volume 15, Issue 8, Pages (December 2012)

Volume 18, Issue 4, Pages (June 2015)

Volume 18, Issue 5, Pages (July 2015)

Volume 15, Issue 2, Pages (March 2012)

Mapping from the Health Assessment Questionnaire to the EQ-5D: The Impact of Different Algorithms on Cost-Effectiveness Results Becky Pennington, MSc,

Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-

Volume 17, Issue 2, Pages (March 2014)

Volume 14, Issue 1, Pages (January 2011)

Volume 18, Issue 4, Pages (June 2015)

Volume 15, Issue 1, Pages S20-S28 (January 2012)

Volume 14, Issue 4, Pages (June 2011)

Volume 14, Issue 8, Pages (December 2011)

Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia Juan-Carlos Castro, MD,

Volume 17, Issue 8, Pages (December 2014)

Volume 14, Issue 4, Pages (June 2011)

Volume 15, Issue 2, Pages (March 2012)

Volume 15, Issue 6, Pages (September 2012)

Volume 15, Issue 1, Pages (January 2012)

Volume 15, Issue 2, Pages (March 2012)

Volume 17, Issue 2, Pages (March 2014)

Examining the Value of Menopausal Symptom Relief Among US Women

Volume 17, Issue 2, Pages (March 2014)

Cost Utility of Sirolimus versus Tacrolimus for the Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico Kely Rely, Rosa María.

The Health Economic Impact of Universal Infant Vaccination with the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine.

Value in Health Regional Issues

Value in Health Regional Issues

Using Dynamic Transmission Modeling to Determine Vaccination Coverage Rate Based on 5-Year Economic Burden of Infectious Disease: An Example of Pneumococcal.

Systematic Review of Economic Evaluation Literature in Ghana: Is Health Technology Assessment the Future? Emmanuel Ankrah Odame, MBCHB, MPH Value in.

The Cost-Effectiveness Analysis of a Quadrivalent Human Papillomavirus Vaccine (6/11/16/18) for Females in Japan Kaoru Yamabe, MSc, Puneet K. Singhal,

Cost-Effectiveness Analysis of Hepatitis B Immunization in Vietnam: Application of Cost- Effectiveness Affordability Curves in Health Care Decision Making

Prevalence, Awareness, Treatment, and Burden of Major Depressive Disorder: Estimates from the National Health and Wellness Survey in Brazil Ronaldo K.

Cost Utility of Sirolimus versus Tacrolimus for the Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico Kely Rely, Rosa María.

The Process of Privatization of Health Care Provision in Poland

Ernest Attuquaye Quaye, BPharm, MPH, Edward O

Value in Health Regional Issues

Cost-Effectiveness of Routine Screening for Cardiac Toxicity in Patients Treated with Imatinib in Brazil Eduardo Gehling Bertoldi, MD, MSc, Milena S.

Value in Health Regional Issues

Cost-Effectiveness Analysis of a Screening Program for Breast Cancer in Vietnam Lan Hoang Nguyen, Wongsa Laohasiriwong, John Frederick Stewart, Pamela.

Value in Health Regional Issues

Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore Vivianne Shih, PharmD, BCOP, BCPS, Alexandre Chan, PharmD,

Cost-Effectiveness Analysis of Atorvastatin versus Rosuvastatin in Primary and Secondary Cardiovascular Prevention Populations in Brazil and Columbia

Bernadette A. Tumanan-Mendoza, MD, MScE, MHE, Victor L. Mendoza, MD

Omneya Mohamed, PhD, David H. Kreling, PhD

Onur Baser, MS, PhD, Akif Altinbas, MD, Erdem Baser, MS, M

Value in Health Regional Issues

Cost-Effectiveness of Biologic Agents in the Treatment of Moderate-to-Severe Psoriasis: A Brazilian Public Health Service Perspective Bruno Salgado Riveros,

Generalized Cost-Effectiveness Analysis of Pharmaceutical Interventions for Primary Prevention of Cardiovascular Disease in Thailand Panrasri Khonputsa,

Cost-Utility Analysis of Pharmaceutical Care Intervention Versus Usual Care in Management of Nigerian Patients with Type 2 Diabetes Maxwell O. Adibe,

Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia Juan-Carlos Castro, MD,

Economic Evaluation of Pravastatin for Primary Prevention of Coronary Artery Disease Based on Risk Prediction from JALS-ECC in Japan Yoshie Onishi, MS,

The Cost-Effectiveness and Budget Impact of Introducing Indacaterol into the Colombian Health System Juan Guillermo Ariza, MD, MSc, Per-Olof Thuresson,

Guidance Document: Global Pharmacoeconomic Model Adaption Strategies

Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea Ji Haeng Heo, MS, Karen L.

Dossier System as a Practical Tool for Compiling Reimbursement Lists

Cost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not.

Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico

Social Cost of Substance Abuse in Russia

Economic Evaluation of Four Drug Administration Systems in Intensive Care Units in Colombia Diego Rosselli, MD, MSc, Juan David Rueda, MD, María Daniela.

Victoria I. Ignatyeva, MPH, Johan L

Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Asthma in Japan and the Value of Responder Prediction Methods Based on a Multinational.

Cost-Effectiveness of the Combined Use of Warfarin and Low-Dose Aspirin versus Warfarin Alone in Egyptian Patients with Aortic Valve Replacements: A Markov.

Abdol Majid Cheraghali, PhD, Peyman Eshghi, MD

Presentation transcript:

Volume 14, Issue 8, Pages 1019-1027 (December 2011) Cost-Effectiveness Analysis of a Universal Infant Immunization Program with Meningococcal C Conjugate Vaccine in Brazil Patricia Coelho de Soarez, MPH, PhD, Ana Marli C. Sartori, PhD, Laura de Andrade Lagoa Nóbrega, MD, Alexander Itria, MS, Hillegonda Maria Dutilh Novaes, PhD Value in Health Volume 14, Issue 8, Pages 1019-1027 (December 2011) DOI: 10.1016/j.jval.2011.05.045 Copyright © 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 1 Simplified diagram of the decision tree model used to analyze the cost-effectiveness of a meningococcal C universal vaccination program in children younger than 1 year in Brazil. Value in Health 2011 14, 1019-1027DOI: (10.1016/j.jval.2011.05.045) Copyright © 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 2 Results of a sensitivity analysis according to the parameter variation. The values for parameters are presented in Table 1. The Word Health Organization threshold value for cost-effectiveness suggests that interventions costing less than three gross domestic products (GDPs) per capita for each disability-adjusted life-year averted is a cost-effective intervention, and interventions costing les than one GDP per capita for each DALY averted is a very cost-effective intervention [32]. The 2006 Brazilian GDP per capita is R$12,688. Value in Health 2011 14, 1019-1027DOI: (10.1016/j.jval.2011.05.045) Copyright © 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 3 The impact of the cost per vaccine dose on the incremental cost-effectiveness ratio per life-year saved from society's perspective. The Word Health Organization threshold value for cost-effectiveness suggests that an intervention costing less than three gross domestic products (GDPs) per capita for each disability-adjusted life-year averted is a cost-effective intervention, and an intervention costing less than one GDP per capita for each disability-adjusted life-year averted is a very cost-effective intervention [32]. The 2006 Brazilian GDP per capita is R$12,688. Value in Health 2011 14, 1019-1027DOI: (10.1016/j.jval.2011.05.045) Copyright © 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 4 Cost-effectiveness acceptability curve for vaccination strategies. Value in Health 2011 14, 1019-1027DOI: (10.1016/j.jval.2011.05.045) Copyright © 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions